ArticleGerms2019
Dissemination of carbapenem-resistant
Article in Germs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Antibiotic-resistant Acinetobacter calcoaceticus-baumannii complex in the environment: a narrative review.FEMS microbiology ecology · 2026Review
- Carbapenemase-mediated resistance in Acinetobacter baumannii clinical isolates: molecular epidemiology and antimicrobial potential of chitosan nanoparticles.BMC microbiology · 2026Article
- Epidemiology and risk factors of multidrug-resistant Gram-negative bacilli in healthcare-associated infections: development of an exploratory risk assessment model in a Moroccan regional hospital.BMC infectious diseases · 2025Article
- In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Article
- First report of SPM metallo-β-lactamases producingIranian journal of microbiology · 2022Article
- Antimicrobial resistance among GLASS pathogens in Morocco: an epidemiological scoping review.BMC infectious diseases · 2022Article
- Molecular Characterization of Gene-Mediated Resistance and Susceptibility of ESKAPE Clinical Isolates toEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Development and Clinical Application of a Recombinase Polymerase Amplification-Lateral Flow Strip Assay for Detection of Carbapenem-ResistantFrontiers in cellular and infection microbiology · 2022Article
- Molecular Characterization of Carbapenem-ResistantInfection and drug resistance · 2022Review
- Dissemination of Carbapenemases (OXA-48, NDM and VIM) ProducingAntibiotics (Basel, Switzerland) · 2021Article
- First report of bla GES-1 in Proteus mirabilis clinical isolates.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- Detection of metallo-beta lactamases and oxacillinase genes in carbapenem-resistantThe Pan African medical journal · 2021Article
- Carbapenemase-Producing Non-Glucose-Fermenting Gram-Negative Bacilli in Africa,International journal of microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsAll strains of
resultsCarbapenem resistance was observed in 23 clinical
conclusionsThis study established baseline proof of three classes of carbapenemases producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.